Last $3.62 USD
Change Today -0.20 / -5.24%
Volume 129.2K
ROSG On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Open
$3.80
Previous Close
$3.82
Day High
$3.80
Day Low
$3.54
52 Week High
03/19/14 - $6.69
52 Week Low
11/20/13 - $2.35
Market Cap
42.2M
Average Volume 10 Days
134.7K
EPS TTM
--
Shares Outstanding
11.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; and a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

45 Employees
Last Reported Date: 03/31/14
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rosetta genomics ltd (ROSG) Key Developments

Rosetta Genomics, Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Rosetta Genomics, Ltd. announced unaudited consolidated earnings results for the six months ended June 30, 2014. For the six months, the company reported revenues of $554,000 against $193,000 a year ago. Operating loss was $7,240,000 against $6,670,000 a year ago. Loss from continuing operations was $7,184,000 or $0.66 basic and diluted per share against $6,566,000 or $0.71 basic and diluted per share a year ago. Net loss after discontinued operations was $7,184,000 or $0.66 basic and diluted per share against $6,293,000 or $0.68 basic and diluted per share a year ago. Non-GAAP net loss was $6,735,000 or $0.62 basic and diluted per share against $5,882,000 or $0.64 basic and diluted per share a year ago. Net cash used in operating activities was $7,561,000 against $4,590,000 a year ago. Purchase of property and equipment was $74,000 against $290,000 a year ago. The company provided earnings guidance for the year 2014. Throughout the balance of 2014 Rosetta Genomics plans to continue to invest in the expansion of its U.S. commercial operations and to fund further clinical development of its microRNA technology. As a result, the company estimates that total net cash requirements to fund operations for the year 2014 will be between $14 million and $15 million, which includes the net cash used to fund operations for six months ended June 30, 2014. Rosetta Genomics believes that its cash balance as of June 30, 2014, combined with projected revenue growth, will be sufficient to fund operations into 2016.

Rosetta Genomics, Ltd. to Report First Half, 2014 Results on Sep 17, 2014

Rosetta Genomics, Ltd. announced that they will report first half, 2014 results on Sep 17, 2014

Rosetta Genomics, Ltd., H1 2014 Earnings Call, Sep 18, 2014

Rosetta Genomics, Ltd., H1 2014 Earnings Call, Sep 18, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $3.62 USD -0.20

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $20.90 USD -0.88
Genomic Health Inc $29.16 USD +0.20
NeoGenomics Inc $5.57 USD +0.12
Response Genetics Inc $0.78 USD +0.0401
Veracyte Inc $10.27 USD +0.01
View Industry Companies
 

Industry Analysis

ROSG

Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.1x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit www.rosettagenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.